Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357572 | 0.91 | PIK3CA (0.52) | ADORA3LMNAMAPKAPK2PIK3R1PIK3CA | |
| SCHEMBL4357305 | 0.90 | MAPT (0.46) | ADORA3LMNAMAPKAPK2PIK3R1PIK3CA | |
| SCHEMBL4367764 | 0.88 | MTOR (0.49) | MAPKAPK2PIK3R1PIK3CAMTORAKT1 | |
| SCHEMBL4351226 | 0.87 | PIK3CA (0.57) | LMNAMAPKAPK2PIK3R1PIK3CAMTOR | |
| SCHEMBL4353441 | 0.87 | AKT1 (0.47) | PIK3R1PIK3CAMTORAKT1EGLN1 | |
| SCHEMBL4357956 | 0.86 | EGLN1 (0.48) | PIK3R1PIK3CAMTORAKT1EGLN1 | |
| SCHEMBL4349968 | 0.85 | ACHE (0.48) | ADORA3LMNAPIK3R1PIK3CAMTOR | |
| SCHEMBL4356704 | 0.83 | PIK3R1 (0.45) | ADORA3LMNAPIK3R1PIK3CAMTOR | |
| SCHEMBL4355558 | 0.82 | SMN1; SMN2 (0.52) | AKT1MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18041199 | 0.82 | LMNA (0.41) | ADORA3LMNAMAPKAPK2PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | claimed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | claimed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | claimed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | ADORA3 442/4885LMNA 2251/4885MAPKAPK2 3575/4885 |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR5A2, NR4A1 | ADORA3 659/4885LMNA 2409/4885MAPKAPK2 3670/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | ADORA3 449/4885LMNA 2425/4885MAPKAPK2 3648/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | ADORA3 449/4885LMNA 2425/4885MAPKAPK2 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.